Viewing Study NCT05422794

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:44 AM
Ignite Modification Date: 2026-02-26 @ 4:18 PM
Study NCT ID: NCT05422794
Status: RECRUITING
Last Update Posted: 2025-10-27
First Post: 2022-06-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anatomic Stage III Breast Cancer AJCC v8 View
None Anatomic Stage IV Breast Cancer AJCC v8 View
None Locally Advanced Triple-Negative Breast Carcinoma View
None Metastatic Triple-Negative Breast Carcinoma View
None Unresectable Triple-Negative Breast Carcinoma View
Keywords: